Background: In the early stages of the 2009 influenza pandemic, little was known about the pandemic (H1N1) 2009 virus or its response to neuraminidase inhibitor therapy.
Methods: Between April 2009 and August 2010, we conducted an open-label study of the response to oseltamivir therapy when administered at the recommended dose or at double the recommended dose twice daily for 5 days.
Results: Thirty-eight patients aged 5 years or older with laboratory-confirmed pandemic (H1N1) 2009 influenza were randomly assigned to treatment. After 5 days, substantial reductions in viral load and clinical signs and symptoms of influenza were observed in the standard- and double-dose groups relative to baseline values. The double-dose regimen did not provide additional benefit over the standard-dose regimen. No resistant viruses were detected. Both regimens were well tolerated, and no serious adverse events were reported.
Conclusions: Standard- and double-dose oseltamivir regimens were well tolerated in this patient group.